VJHemOnc is committed to improving our service to you

ASH 2019 | Is it prime-time for CAR-T in myeloma?

VJHemOnc is committed to improving our service to you

Nina Shah

Nina Shah, MD, University of California-San Francisco, San Francisco, CA, gives an overview of the CAR T-cell therapy landscape in multiple myeloma (MM) and what we can expect to see in the future. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter